

## REVIEW

# Emerging Concepts in Metformin Therapy: Hyperglycaemia and Beyond

Tarek M. Fiad, Fatema H. Al Hammadi, Asma A. Al Nuaimi, Jamila S. Al Dhuhouri

Center for Diabetes and Endocrinology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

Corresponding author: Dr Tarek M. Fiad      Email: tarekmfiad@gmail.com

Published: 31 July 2013

Ibnosina J Med BS 2013,5(4):227-239

Received: 26 July 2013

Accepted: 27 July 2012

This article is available from: <http://www.ijmbs.org>

This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

Metformin has been extensively used in the management of type 2 diabetes mellitus (T2DM). A number of properties combined, including cost effectiveness, safety, weight neutrality, low risk of Hypoglycemia and cardiovascular protection moved metformin to the forefront of diabetes management and is now accepted as the standard first line therapy. Although other classes of glucose lowering medications were introduced to clinical practice in the recent times, none of such therapies has as yet demonstrated superiority to metformin to justify being considered as a first line therapeutic option. The use of metformin has extended in the last 2 decades to include diabetes prevention, gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS). There is accumulating evidence from observational studies to suggest a possible role for metformin in cancer prevention and in the management of non-alcoholic fatty liver disease. We reviewed the role of metformin in the prevention and treatment of T2DM

and allied metabolic disorders and examined the non-glycaemic effects of metformin. In addition, we reviewed safety aspects pertinent to the usage of metformin in special clinical settings.

**Keywords:** Metformin, type 2 diabetes, Insulin resistance, Cardiovascular protection, Cancer, Gastrointestinal intolerance, Lactic acidosis, Gestational diabetes mellitus.

## Introduction

Metformin is among a few medications which enjoyed long-term wide acceptance owing to its favourable glycaemic effects and safety alike. It is ranked among the top 10 generic drug prescriptions in the United States in 2009 with more than 42 million prescriptions (1). It belongs to the biguanide group of medications, the other being phenformin which was withdrawn from use because of serious adverse effects (2, 3). Although metformin use spanned many decades, its defined role in cardiovascular protection only came to light

in United Kingdom Prospective Diabetes (UKPDS) Study (4). Subsequent to the UKPDS observations, diabetes management guidelines almost unanimously recommended the use of metformin as the first line therapy for T2DM (5-7). In this review, efficacy and safety of metformin will be discussed and emerging evidence regarding its use in glycaemic and non-glycaemic settings will be reviewed.

### **Mechanisms of action and efficacy of metformin**

The effect of metformin on glucose is mediated by improving insulin sensitivity in liver, muscle and fat. Conventionally, metformin is known to reduce glucose concentration through reduction in glucose liver output brought about primarily by reducing the rate of gluconeogenesis and to a lesser extent by reducing glycogenolysis (8). Metformin also augments peripheral glucose utilization in muscle and fat (9,10). More recently, by mechanisms other than dipeptidyl-peptidase-4 (DPP-4) inhibition (11), metformin was shown to increase the level of glucagon-like-peptide-1 (GLP-1) (12). This mechanism of action may explain at least in part some of the metabolic effects of metformin, including weight neutrality and provides a unique advantage when metformin is combined with DPP-4 inhibitors through further enhancement of the incretin axis, which in turn offers the potential for additive glycaemic improvement (13,14).

### **Metformin for the treatment of T2DM and GDM**

#### ***Metformin therapy for T2DM***

Metformin has a number of attractive properties including weight neutrality, no hypoglycaemic reactions and cost-effectiveness making it the first line therapy in subjects with T2DM (5-7, 15). Treatment with metformin can be initiated at diagnosis in patients who have glycosylated haemoglobins (HbA1c) above 7.5% who are unlikely to be motivated enough to implement lifestyle measures whilst patients with HbA1c <7.5% who are motivated can be offered a 3 month trial of diet and exercise before a decision contemplating initiation of metformin therapies made (7). The glucose lowering efficacy of metformin is dose dependent (16). In addition, the magnitude of HbA1c lowering is dependent on the baseline level with greater lowering being observed in those with higher pre-treatment HbA1c (17). A recent meta-analysis of 35 trials of at least 12 weeks duration quantified the effects of metformin treatment (Figure 1) (18).

Metformin monotherapy reduced HbA1c by 1.12%, and metformin in combination with other oral glucose lowering

therapies or insulin reduced HbA1c by 0.95% and 0.83%, respectively, with the effect being sustained at 24 weeks. In this analysis, the improvement in glycaemic control when metformin was combined with insulin was observed when the treatment protocol allowed for insulin dose adjustment in both metformin treated and untreated arms, which signifies a primary role for metformin in glucose lowering in insulin treated patients. Based on the established evidence, treatment with metformin is advocated at all stages of disease progression and the benefit is observed in both obese and non-obese subjects (19,20). However, metformin should be discontinued if absolute contraindications such as advanced renal disease or decompensated heart failure exist as detailed later.

#### ***Metformin in GDM***


In general, metformin is an appealing therapy and a logical option in pregnancy because of ease of administration and cost effectiveness. Metformin use during pregnancy was found to provide adequate glucose control, less weight gain and lower rates of neonatal Hypoglycemia (21). Evidence from observational studies suggests that babies exposed to metformin in utero exhibited no adverse sequelae in the short term (22,23). Furthermore, smaller randomized studies also supported the notion of Metformin use in pregnancy (24). However, metformin crosses the placenta; therefore the possibility of a delayed or long term risk to babies born to mothers who were treated with metformin during pregnancy cannot be fully ruled out (23). For instance, a recent study reported potential harmful effect of metformin on the development of the fetal testis (25). These observations raise some concern about metformin safety during gestation.

Based on available evidence, some learned societies endorsed the use of metformin in pregnancy. Both the National Institute of Clinical Excellence (NICE) and Canadian Diabetes Association (CDA) include metformin as a therapeutic option in subjects with GDM (26,27). However, other societies such as the American Diabetes Association (ADA) and International Diabetes Federation (IDF) do not make similar recommendations perhaps a reflection of paucity of long term safety data (28,29).

#### ***Metformin use in children and adolescents***

##### ***Metformin in obese children and adolescents without Diabetes***

A number of clinical trials explored the short term role of metformin in the treatment of obesity and insulin



*Protocol-permitted insulin dose adjustments in both arms of these trials*


**Figure 1.** Magnitude of HbA1c lowering with metformin monotherapy, add-on to oral therapy or add-on to insulin: meta-analysis of 35 Trials of at least 12 weeks duration (18)

insensitivity in adolescents and reported modest weight loss with beneficial effects on insulin resistance and associated metabolic abnormalities (30-32). Although in the short-term, the effects of metformin on obesity and related metabolic abnormalities were encouraging, it's unlikely that this effect is maintained in the long term. Furthermore, positive effects of metformin should not take away the importance of lifestyle as the primary means of preventing the epidemics of obesity in this age group. Based on current evidence, metformin cannot be advocated as a therapeutic option in treating obese children and adolescents. Long term and larger studies may help to define a more precise role for metformin in treating metabolically abnormal and diabetes prone obese adolescents.

#### ***Metformin in adolescents with T2DM***

IDF Guidelines for the management of T2DM in children

and adolescents recommended lifestyle as the initial intervention in this group of patients. This is at variance with the most recently published guidelines by the American Academy of Pediatrics (33), American Diabetes Association and other societies which advocate the use of metformin at diagnosis. Although the guidelines acknowledged the importance of lifestyle, the rationale behind commencing metformin at diagnosis was based on the high failure rate of lifestyle measures with fewer than 10 % of adolescents with T2DM subjects achieving glycaemic targets through lifestyle alone. Furthermore, even when metformin therapy is instituted at diagnosis, the glycaemic effect is unlikely to be durable. The recently reported TODAY Trial (Treatment Options for Type 2 Diabetes in Adolescents and Youth) showed that most adolescents with T2DM do not sustain glycemic control with monotherapy and hence is the need for early addition of other glucose lowering agents



**Figure 2.** GI tolerability whilst on metformin XR in patients previously intolerant to immediate release formulation of metformin in five diabetes centers (36,37).

(34). Therefore, based on available evidence, early use of metformin is advocated in most adolescents with T2DM. However, from the safety perspective and whilst non insulin therapies are more appealing to clinicians and patients alike, health care professionals involved in assessing and managing adolescents with assumed diagnosis T2DM should err on the side of caution by using insulin rather than metformin as the initial therapy if uncertainty exists about the nature of diabetes i.e. T1DM or T2DM.

#### **Safety aspects of metformin therapy**

##### ***Gastrointestinal (GI) intolerance and the role of extended release metformin***

The commonest side effect of immediate release (IR) metformin is GI intolerance, with a range of symptoms including bloating, nausea, vomiting and diarrhoea. These

side effects are generally brought about when patients are started on large doses of IR metformin or in the setting of rapid dose escalation. Dose reduction, administering IR metformin with or after meals and slow dose escalation tends to resolve or ameliorate GI side effects. However, approximately 5% of diabetic patients remain intolerant to the IR metformin even when cautious introduction and dose escalation principles are applied. The extended release (XR) formulation is an alternative form of metformin which possesses slower absorption characteristics in the upper gastrointestinal tract thereby allowing for once-daily dosing. XR Metformin has similar metabolic efficacy to the IR formulation and provides similar HbA1c lowering (35). In a study of 63 patients intolerant to IR metformin, 89% of these patients were able to tolerate XR metformin without experiencing GI side effects (figure 2) (36).

**Table 1.** Suggested use of metformin in patients with chronic kidney disease according to stages of kidney disease

CKD Stage	eGFR (ml/min/1.73 m <sup>2</sup> )	Metformin Dose	Precautions and frequency of renal function monitoring
1	≥90	Maximum dose <sup>1</sup>	Annual <sup>2,3</sup>
2	60-89	Maximum dose <sup>1</sup>	Annual <sup>2,3</sup>
3a	45-59	Maximum dose <sup>1</sup>	3-6 months <sup>2,3</sup>
3b	30-44	Half the maximum dose	Every 3 months <sup>2,3</sup> Avoid if unexpected change in eGFR is anticipated, e.g. unstable heart failure, diuretic use or other medications which may affect eGFR
4	15-29	None	
5	<15	None	

1. Maximum dose of metformin is generally 2000 mg per day

2. Apply standard precautions including withholding metformin therapy during episodes of dehydration, e.g. vomiting, gastroenteritis and before administration of contrast media.

3. More frequent monitoring can be applied as dictated by clinical setting.

Similar improvement in GI tolerability was reported by other investigators when subjects were switched from IR to XR metformin (37) (Figure 2). Therefore, in patients experiencing persistent GI side effects with IR Metformin, the XR formulation can be offered as an alternative therapeutic option.

### **Metformin in chronic kidney disease (CKD)**

Metformin is eliminated renally, and rare incidents of lactic acidosis have been described in CKD patients (38). Based on the widely held view that metformin plays a causative role in precipitating lactic acidosis when the kidney function is deranged, restriction on its use was suggested. The food and drug administration in the USA recommended stopping metformin in men and women with serum creatinine concentrations >1.5 and >1.4 mg/dL (>132 and >123 μmol/L), respectively. However, the notion that metformin contributes to lactic acidosis has been challenged. Large meta-analysis and prospective observational studies showed no link between metformin and lactic acidosis in patients with CKD stage 3 (39,40). Clinical studies showed that the risk of lactic acidosis

is similar among metformin and non-metformin users. Furthermore, smaller experimental data suggested no increase in lactic acidosis risk when metformin is used in patients with stable creatinine clearances as low as 20 ml/min/1.73 m<sup>2</sup> (41). On grounds of the reassuring evidence, recent recommendations support metformin dose reduction when creatinine clearance falls below 45 ml/min/1.73 m<sup>2</sup> and stopping metformin when creatinine clearance drops to less than 30 ml/min/1.73 m<sup>2</sup> (42,5). Caution should however be applied in avoiding use of metformin if kidney function is fluctuating and when the possibility of acute or sudden decline in kidney function is anticipated. Other safety measures worthy highlighting include stopping metformin before contrast media administration. Principles of good medical care dictate provision of routine advice to patients regarding with-holding metformin during episodes of dehydration such as with vomiting or gastroenteritis. Suggested guidance on the use of metformin in CKD is summarised in table 1.

### **Metformin in heart failure**

Patients with diabetes are at least twice as likely to develop

heart failure (HF) than patients without diabetes (43). Historically, the concern about the use of metformin in diabetic patients with HF has stemmed from the possible risk of precipitating the potentially fatal complication of lactic acidosis. On those grounds, many diabetes guidelines included HF as an absolute contraindication to metformin therapy. However, studies did not confirm the link between metformin use and lactic acidosis (39). A large recent meta-analysis of 34,504 patients with diabetes and HF concluded that metformin was as safe as other glucose lowering therapies even in those with reduced left ventricular ejection fraction or concomitant CKD (44). Observational study of 10,920 patients in Denmark reported lower mortality in the group of diabetic patients with HF who were treated with metformin compared to treatment with a sulfonylurea or insulin (45). Similar observations were made in a study of 6185 patients with HF and diabetes, where patients treated with metformin had lower rates of mortality at 2 years of follow up (46). The survival benefit was observed across different subgroups of HF, including those with renal insufficiency.

The recently published 2013 ADA guidelines understandably erred on the side of safety by adopting a conservative approach whereby metformin was recommended as a viable option in stable HF if renal function is normal (6). Based on the reassuring evidence that HF patients on metformin fare as well if not better than other glucose lowering therapies, the Canadian Diabetes Association recommends metformin as first line therapy in HF patients with mild to moderate renal dysfunction (27).

#### ***Metformin and deficiency of vitamins***

In T2DM, exposure to metformin has been linked to reduced B12 absorption and the development of biochemical vitamin B12 deficiency. The risk of developing B12 deficiency has been associated with the duration of metformin use (47) and the dose employed (48). On the whole, approximately a quarter of patients on metformin therapy develop a variable degree of B12 deficiency (49). However, whilst classical B12 deficiency presents with clinical symptoms including anaemia, peripheral neuropathy, cognitive dysfunction and depression, not all people with biochemical vitamin B12 deficiency will develop clinical symptoms (50). Presently, there is no evidence to justify routine screening for B12 deficiency as the cost-effectiveness of mass screening and the benefit of treating subclinical deficiency are at best unproven, nonetheless, it is prudent to adopt a targeted screening for those at a particular risk of developing B12

deficiency including patients on long-term high dose metformin therapy especially in the setting of neuropathy, cognitive dysfunction and anaemia. The American Diabetes Association and others recommend checking B12 status in subjects with severe neuropathy especially in those taking metformin for prolonged periods (6,51). Patients with proven B12 deficiency should be treated. Route of B12 administration is a contentious issue. Oral B12 therapy can be effective in correcting B12 deficiency (52,53). It was pointed out that the amount of vitamin B12 included in most of the multivitamins preparations (6 µg) is not adequate to correct existing deficiency (54) and a higher dose of oral B12 (1000 mcg per day) was advocated (55). The other widely accepted form of B12 supplementation is the intramuscular injection which leads to more speedy correction of existing deficiency (56,57).

#### ***Metformin use in disease prevention***

The preventative use of metformin covers three areas namely prevention of T2DM in high risk groups, cardiovascular protection and prevention of cancer.

#### ***Metformin for the prevention of T2DM***

The US Diabetes Prevention Program (DPP) demonstrated that metformin reduces the risk of progression of impaired glucose tolerance (IGT) to diabetes by approximately 31%. This beneficial effect of metformin was mainly observed in subjects with body mass index (BMI) > 35 kg/m<sup>2</sup> and younger than 60 years of age (58). Accordingly, metformin is recommended as a therapeutic option in subjects with impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and those in whom the HbA1c level lies in the pre-diabetes range (5.7-6.4%) (6). In women with past history of GDM, subgroup analysis of the DPP suggested that metformin is associated with 50% risk reduction in progression to diabetes (59). Based on these observations, metformin as well as lifestyle are the tools currently available to prevent progression to diabetes in this group of patients (6). Whilst metformin is considered as a therapeutic option in subjects with pre-diabetes, lifestyle has been shown to be superior to Metformin in preventing diabetes. The DPP, the FINISH and the DaQing intervention trials explored the role of lifestyle intervention in subjects with pre-diabetes and reported a delay in the progression to diabetes of 34%, 38% and 43% at 10, 13 and 20 years respectively (58,60-62). Therefore, this mode of intervention should be explored before considering any pharmacological means. Those who fail life style can reasonably be commenced on metformin.



### ***Cardiovascular outcomes***

The primary objective of intervention in T2DM is the prevention of vascular disease. Whilst studies have confirmed that controlling hypertension and dyslipidemia were associated with significant reduction in cardiovascular complications (63-65), therapy aiming at controlling hyperglycemia did not reach similar conclusions (66-68). Limited data derived from the UKPDS and based on 342 patients initiated on metformin therapy suggested a role for metformin in the prevention of vascular disease and all cause mortality (4). A number of observational studies have suggested a cardio protective effect of metformin in patients with T2DM with high baseline CV risk (69,70). In a randomized, placebo controlled trial, Kooy et al, showed that when metformin was added to insulin, a reduction in macrovascular disease was observed (71). On the contrary, a recent meta-analysis of 13,110 patients did not support a role for metformin in reducing all cause and cardiovascular mortality (72). Differences in patients' characteristics and study design may conceivably explain the inconsistency in reporting metformin benefit. Furthermore, the observations made in this meta-analysis should not detract physicians from using metformin as the number one therapy of choice giving its long tract safety record and affordability. Ongoing CV outcome trials using newer diabetes medications may lead to the reappraisal of preferred therapy choices.

### ***Metformin and cancer***

Vascular complications are the leading cause of death in diabetes (73). With the improved control of vascular risk factors (74) we are witnessing the emergence of cancer as an important cause of morbidity and mortality in diabetes (73). Epidemiological data suggests that many types of cancer occur with a higher frequency in people with diabetes including cancer of the liver, pancreas, colon, breast, kidney, bladder, uterus and ovary (75,76). The precise aetiology for the observed increase in cancer risk in diabetes is not well understood, however a number of aetiological factors have been advanced including Hyperglycemia (77,78), hyperinsulinaemia (78) inflammation and oxidative stress (79). It is plausible that therapies which control such risk factors may potentially prove to possess anti-tumour properties. In this context, in the analysis of the DART study (Diabetes Audit and Research in Tayside Study) participants, potential benefit of metformin was first described by Evans et al (80) who reported a dose-dependent reduction in cancer risk. Numerous subsequent observational studies demonstrated a reduced risk of breast (81), Colonic (82) and liver cancers (83). Investigators

in the ZODIAC (Zwolle Outpatient Diabetes Project Integrating Available Care) study made two observations: first, patients with T2DM are at a greater risk of cancer, and second, metformin users had lower cancer mortality compared with nonusers (84). Whilst the observational data hints to an important role for metformin as an anti-cancer agent, causal association whereby metformin directly lowers cancer risk cannot be proven. The possibility always exists that observational data can suffer from the effect of unmeasured confounders which in turn may lead to erroneous and misleading results. Therefore, while the perceived effect of metformin on cancer risk is reassuring, drawing firm conclusion on the effect of metformin on cancer requires the conduction of prospective randomized studies. In the meantime, metformin will continue to retain pole position thanks to its long track record as one of the most efficacious, safest and least expensive diabetes therapy.

### ***Miscellaneous Issues***

Finally, three remaining topical issues will be discussed, these are the role of metformin in PCOS, the potential use of metformin in nonalcoholic fatty liver disease (NAFLD) in adults and adolescents and the safety of metformin use by breast feeding mothers.

### ***Metformin in PCOS***

PCOS is by far the commonest condition that leads to ovulatory failure. Underlying abnormalities playing a role in the pathogenesis of PCOS include luteinizing hormone hypersecretion (85), primary adrenal and ovarian abnormalities (86-88) and insulin resistance which is out of proportion to what is predicted from the prevailing BMI (89). Given that insulin resistance is common in PCOS and that the severity of this disorder is directly correlated with the degree of insulin resistance (90, 91), it makes sense to explore the therapeutic advantages of medications with insulin sensitising properties. From the reproductive prospective, anovulatory women with PCOS seeking fertility should be offered clomiphene citrate therapy along with lifestyle as the preferred ovulatory induction option. If reduced multiparity is deemed a necessity, metformin can be considered as an alternative first line agent for ovulation induction (92,93). The use of metformin as a first line therapy for ovulation induction can also be considered in anovulatory women with BMI<30 (94).

### ***Metformin in NAFLD in adults and adolescents***

NAFLD is a disorder which encompasses a spectrum

of fatty liver disorders ranging from fatty liver at one end to steatohepatitis and cirrhosis at the other end in the absence of excessive alcohol consumption. The risk of NAFLD in diabetes has been reported to be as high as 70%. In the setting of T2DM, patients with NAFLD are more likely to develop more advanced liver disease associated with fibrosis, cirrhosis and in some instances hepatocellular carcinoma. Therefore, early diagnosis of NAFLD is important in allowing for instituting timely intervention aiming at not only prevention of liver disease progression but also to recognize patients at higher risk for cardiovascular disease who warrant early intervention (95). Studies using metformin in treatment of NAFLD have demonstrated improvement in liver enzymes, however, not all trials showed an improvement in liver histology (96-101). Studies of 6 months duration using metformin up to 1.7 gm/day failed to demonstrate regression in histological abnormalities (98). On the other hand, longer duration trials spanning 12 months and using a higher dose of metformin i.e. 2 grams/day showed histological improvement (102, 103). Furthermore, observational studies showed a reduction in the risk of developing Hepatocellular carcinoma (HCC) and all liver cancers in subset of patients exposed to metformin treatment (82). Based on the existing evidence, larger long term randomized studies are required to establish the role of metformin in treating NAFLD. In the absence of such an evidence, and based on the encouraging results from smaller studies, metformin should be considered as an adjunct therapy to lifestyle and weight reduction in NAFLD associated with diabetes.

### ***Metformin and breast feeding***

Few studies looked at the safety of metformin during lactation. A study of five nursing mothers by Hale et al. showed that infants' exposure to metformin was only 0.28% of the weight- normalized maternal dose and considered this value to be well below the 10% level of concern in breast feeding (104, 105). Similar observations were made by Briggs et al. who also showed that infants' exposure to metformin was below 1% of the maternal weight – adjusted dose and such a small exposure led to no decline in blood glucose level in the 3 studied infants (106). In another small study of 3 nursing mothers, Gardiner et al. made the observation that there was a steady level of metformin concentration in the breast milk implying that the time of metformin ingestion by the mother has no bearing on the amount of metformin detected in breast milk (107). In a relatively larger study looking at growth, motor and social development, Glueck et al. observed no differences in

outcomes between breast- and formula-fed infants at 3 and 6 months of age (108). Based on no demonstrable adverse signals, the NICE Guidelines suggest that women with pre-existing T2DM who are breastfeeding can resume or continue to take metformin. The guidelines also recommend obtaining an informed consent on the use of metformin during lactation, a practice which is probably not widely implemented by clinicians (26). In summary, although metformin appears to be safe during lactation, randomized prospective longer term trials will help in drawing a more robust conclusion.

### ***Metformin in non diabetic obesity***

Most of the studies examining the role of metformin in primary obesity were of short duration and included small number of patients. Some of these studies reported meaningful weight loss which is comparable to what is achieved with the use of established anti-obesity medications (109-111). The net weight loss reported in other studies was not different from placebo, perhaps a reflection of study design and/or patients population (112). Long-term large randomised trials exploring the use of metformin in obesity are lacking. Therefore the totality of available evidence does not support a definitive role for metformin in the treatment of primary obesity (110-115).

### **Final remarks and conclusions**

Metabolic and cardiovascular properties of metformin are undisputed, hence is the unanimous endorsement by all diabetes societies and guidelines in recommending metformin as the first therapy of choice in subjects with T2DM. Established safety of metformin in mild to moderate CKD, in stable heart failure and the availability of slow release formulation of metformin allowed for wider use of this product in special settings. Use of metformin has extended recently to encompass other entities including pre-diabetes, GDM and PCOS. Encouraging evidence, albeit limited, suggests a possible favourable effect of metformin in cancer, NAFLD, and obesity. Whether randomised trials confirm this perceived benefit remains to be ascertained.

### **References**

1. No author. 2009 Top 200 generic drugs by total prescriptions. Drug Topics 2010:1-3.
2. Kwong, S.C. and Brubacher, J. Phenformin and lactic acidosis: a case report and review. J Emerg Med 1998;16:881-6.
3. University Group Diabetes Program. A study of



- the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: V. Evaluation of phenformin therapy. *Diabetes* 1975;24:65-184.
4. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352:854-65.
  5. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. [cited 2013 Jul 1]. Available from: <http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf/>.
  6. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care* 2013; 36: S11-66.
  7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364-79.
  8. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. *Diabetes Metab* 2003;29:628-35.
  9. Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. *Metabolism* 1993;42:1217-22.
  10. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. *Diabetes Metab* 1991;17:180-4.
  11. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. *Biochem Biophys Res Commun* 2002;298:779-84.
  12. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. *Clin Pharmacol Ther* 2010;88:801-8.
  13. Goldstein BJ, Feinglos MN, Luncford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007;30:1979-87.
  14. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:442-51.
  15. AACE Comprehensive Diabetes Management Algorithm, *Endocr Pract* 2013;19:327-36.
  16. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. *Am J Med* 1997;103:491-7.
  17. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. *Diabetes Care* 2006;29:2137-9.
  18. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Care* 2012;35:446-54.
  19. Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, et al. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. *Nutr Metab* 2010; 7:83.
  20. Kooy A. Continuation of metformin after introduction of insulin in type 2 diabetes. *BMJ* 2009 9;339:b4227.
  21. Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Vieira Francisco RP. Randomized trial of metformin vs insulin in the management of gestational diabetes. *Am J Obstet Gynecol*. 2013 Mar 21. pii: S0002-9378(13)00296-2.
  22. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. *Hum Reprod* 2004;19:1323-30.
  23. Rowan JA, Rush EC, Obolonkin V, Battin M, Woudes T, Hague WM. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. *Diabetes Care* 2011;34:2279-84.
  24. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med* 2008; 358:2003-15.

25. Tartarin P, Moison D, Guibert E, Dupont J, Habert R, Rouiller-Fabre V, et al. Metformin exposure affects human and mouse fetal testicular cells. *Hum Reprod.* 2012;27:3304-14.
26. National Collaborating Centre for Women's and Children's Health. Diabetes in pregnancy. Revised reprint July 2008. London: RCOG Press. ([www.nice.org.uk](http://www.nice.org.uk)).
27. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. *Can J Diabetes* 2008; 32: S168-80.
28. American Diabetes Association. Gestational diabetes mellitus. *Diabetes Care* 2003;26:S103-5.
29. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline on Pregnancy and Diabetes. Brussels, Belgium: International Diabetes Federation; 2009.
30. Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Iverson F, et al. Metformin in Obese Children and Adolescents: The MOCA Trial. *J Clin Endocrinol Metab.* 2013;98:322-9.
31. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. *Diabetes Care* 2009;32:1743-5.
32. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. *Pediatrics* 2001;107:E55.
33. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *Pediatrics* 2013;131:364-82.
34. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain glycaemic control in youth with type 2 diabetes. *N Engl J Med* 2012;366:2247-56.
35. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr* 2010;2:16.
36. Ashawesh K, Taylor J, Huckerby Cand Fiad T. Tolerability of metformin SR in patients with type 2 diabetes. *Pract Diab Int* 2008;25: 249.
37. Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin – results from four UK centres. *Br J Diabetes Vasc Dis* 2007;7:225-8.
38. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. *Drug Saf* 2010;33:727-40.
39. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. *Arch Intern Med* 2003;163:2594-602.
40. Arroyo D, Melero R, Panizo N, Goicoechea M, Rodríguez-Benítez P, Vinuesa SG, et al. Metformin-associated acute kidney injury and lactic acidosis. *Int J Nephrol* 2011;2011:749653.
41. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, et al. Metformin therapy in patients with chronic kidney disease. *Diabetes Obes Metab* 2012:963-5.
42. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. *Diabetes Care* 2011;34:1431-7.
43. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. *Diabetes Care* 2004; 27:1879-84.
44. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. *Circ Heart Fail* 2013;6:395-402.
45. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. *Diabetologia* 2010;53:2546-53.
46. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. *Circ Heart Fail.* 2011;4:53-8.
47. De Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ* 2010;340:c2181.
48. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. *Arch Intern Med* 2006;166:1975-9.

49. Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Seaquist D, Topolski R. The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. *J Am Board Fam Med* 2009;22:528-34.
50. Carmel R. Mandatory fortification of the food supply with cobalamin: an idea whose time has not yet come. *J Inher Metab Dis* 2011;34:67-73.
51. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. *Diabetes Care* 2010;33:156-61.
52. Jawa AA, Akram J, Sultan M, Humayoun MA, Raza R. Nutrition-related vitamin B12 deficiency in patients in Pakistan with type 2 diabetes mellitus not taking metformin. *Endocr Pract* 2010;16:205-8.
53. Fitzgerald MA. Drug-induced vitamin B12 deficiency. *Nurse Pract* 2007;32:6-7.
54. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley Jr GP. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. *Diabetes Care* 2012;35:327-33.
55. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood* 1998;92:1191-8.
56. Mahajan R, Gupta K. Revisiting metformin: Revisiting Metformin: Annual Vitamin B12 Supplementation may become Mandatory with Long-Term Metformin Use. *J Young Pharm* 2010;2:428-9.
57. Stabler SP. Vitamin B12 deficiency. *N Engl J Med* 2013;368:2041-2.
58. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393-403.
59. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 2008;93:4774-9.
60. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009; 374:1677-86.
61. Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). *Diabetologia*. 2013;56:284-93.
62. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. *Lancet* 2008;371:1783-9.
63. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998;317:713-20.
64. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007;370:829-40.
65. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7-22.
66. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59.
67. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560-72.
68. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129-39.
69. Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR Jr, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. *Am J Cardiol*. 2004;93:1347-50.
70. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. *Diabetes Care* 2002;25:2244-8.
71. Kooy A, de Jager J, Leher P, Bets D, Wulffélé MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes

- mellitus. *Arch Intern Med* 2009;169:616-25.
72. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med* 2012;9(4):e1001204.
  73. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011;364:829-41.
  74. Vamos EP, Millett C, Parsons C, Aylin P, Majeed A, et al. Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009. *Diabetes Care* 2012;35:265-72.
  75. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol* 2004;159:1160-7.
  76. Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? *Diabet Med* 2011;28:276-86.
  77. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? *JAMA* 2010;303:446-7.
  78. Giovannucci E, Harlan DM, Archer MC, Bergental RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. *Diabetes Care* 2010;33:1674-85.
  79. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? *Free Radic Biol Med* 2010;49:1603-16.
  80. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005;330:1304-5.
  81. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care* 2010;33:1304-8.
  82. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. *Diabetes Care* 2011;34:2323-8.
  83. Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2012;97:2347-53.
  84. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. *Diabetes Care* 2010;33:322-6.
  85. Fiad TM, Cunningham SK, McKenna TJ. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. *Eur J Endocrinol* 1996;135:335-9.
  86. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. *Endocr Rev* 1995;16:322-53.
  87. Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. *Rev Endocr Metab Disord* 2007;8:331-42.
  88. McKenna TJ, Cunningham SK. Adrenal androgen production in polycystic ovary syndrome. *Eur J Endocrinol* 1995;133:383-9.
  89. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. *Fertil Steril* 2005;83:1454-60.
  90. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. *J Clin Endocrinol Metab* 1991;73:590-5.
  91. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. *J Clin Endocrinol Metab* 1987;65:499-507.
  92. Nestler JE. Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. *Fertil Steril* 2008;90:14-6.
  93. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. *Endocr Rev*. 2009;30:1-50.
  94. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Cochrane Database Syst Rev*. 2012;16(5):CD003053.
  95. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med*. 2002;346:1221-31.
  96. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, et al. Metformin versus dietary treatment



- in nonalcoholic hepatic steatosis: a randomized study. *Int J Obes*. 2010;34:1255-64.
97. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. *Lancet* 2001;358:893-4.
  98. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2004;19:537-44.
  99. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. *Ann Hepatol* 2007;6:222-6.
  100. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2008;28:200-8.
  101. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjørø K, Haaland T, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scand J Gastroenterol* 2009;44:853-60.
  102. Bugianesi E, Gentilecore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. *Am J Gastroenterol* 2005;100:1082-90.
  103. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2009;29:172-82.
  104. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. *Diabetologia* 2002;45:1509-14.
  105. Ito S. Drug therapy for breast-feeding women *N Engl J Med*. 2000;343:118-26.
  106. Briggs GG, Ambrose PJ, Nageotte MP, Padilla G, Wan S. Excretion of metformin into breast milk and the effect on nursing infants. *Obstet Gynecol* 2005;105:1437-41.
  107. Gardiner SJ, Kirkpatrick CM, Begg EJ, Zhang M, Moore MP, Saville DJ. Transfer of metformin into human milk. *Clin Pharmacol Ther* 2003;73:71-7.
  108. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. *Expert Opin Drug Saf* 2007;6:191-8.
  109. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. *Exp Clin Endocrinol Diabetes* 2013;121:27-31.
  110. Gokcel A, Gumurdulu Y, Karakose H, Melekertorer E, Tanaci N, Bascil Tutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. *Diabetes Obes Metab* 2002;4:49-55.
  111. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000;85:2767-74.
  112. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, Cohen JM, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. *BIGPRO Study Group. Diabetes Care* 1996;19:920-6.
  113. Golay A. Metformin and body weight. *Int J Obes (Lond)* 2008;32:61-72.
  114. Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D'Amico F, Wilson SA. Metformin as treatment for overweight and obese adults: a systematic review. *Ann Fam Med* 2005;3:457-61.
  115. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. *Metabolism* 2001;50:856-61.